Prophylactic treatment of migraines (with or without aura). Treatment of diabetic retinopathy at an early stage.
Composition:
1 tabl contains 2.5 mg of irazochrome. The preparation contains lactose.
Action:
Antimigraine drug. Irazochrome prevents local metabolic disorders in the pathomechanism of migraine. It blocks the biogenic amines and therefore inhibits chemoreceptor stimulation, increase vascular permeability and the development of peripheral edema. Irazochrome has serotonin antagonistic activity and reduces the permeability and fragility of blood vessels in the capillary system. After oral administration on an empty stomach, irazole is rapidly absorbed. Cmaxoccurs after 1 hour after administration. T0,5 is 2.2 ± 0.5 h. About 20% of the administered dose is excreted unchanged by the kidneys.
Contraindications:
Hypersensitivity to iprazochrom, other derivatives of adrenochrome or other components of the preparation. Pregnancy and lactation. Children under 18 years.
Precautions:
Due to the lactose content, the drug should not be used in patients with rare hereditary galactose intolerance, lactase deficiency (Lapp type) or malabsorption of glucose-galactose.
Pregnancy and lactation:
There is no evidence of embryotoxicity, however, due to the lack of sufficient experience, iprazochrome is not recommended in pregnant or breast-feeding women.
Side effects:
Rare: allergic drug rash (resolving a few days after discontinuation of the drug). Very rare: loss of appetite (at the beginning of treatment). During treatment, reddish-brown urine may appear, this means that the active substance is excreted in the urine.
Dosage:
Orally. Adults.Migraine: 1-2 tabl. (maximum 3 tables) 3 times a day. The preparation relieves symptoms but does not completely eliminate them, simultaneous administration of other seizures is recommended if necessary.Diabetic retinopathy: 2 tabl. 3 times a day. If the treatment is successful, after a few months the dose can be reduced to 1 tablet. 3 times a day. The tablets should be swallowed whole with a small amount of liquid. The preparation is intended for long-term treatment, its effectiveness increases with the duration of treatment. Decrease of seizure frequency should occur after 4 weeks of treatment and full effectiveness after 3 months.
(C)
